跳转至内容
Merck
CN

G7048

氯胍 盐酸盐

≥95% (HPLC)

别名:

Chlorguanide, N1-(4-Chlorophenyl)-N5-isopropylbiguanide

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式(希尔记法):
C11H16ClN5·HCl
化学文摘社编号:
分子量:
290.19
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51101906
EC Number:
211-283-7
MDL number:
Assay:
≥95% (HPLC)
Form:
solid
Quality level:
Storage condition:
desiccated
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Level

assay

≥95% (HPLC)

form

solid

storage condition

desiccated

solubility

acetonitrile: water: ~1 mg/mL (60/40)

originator

AstraZeneca

storage temp.

2-8°C

SMILES string

Cl.CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1

InChI

1S/C11H16ClN5.ClH/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9;/h3-7H,1-2H3,(H5,13,14,15,16,17);1H

InChI key

SARMGXPVOFNNNG-UHFFFAOYSA-N

Application

Proguanil (chlorguanide) may be used in anti-parasitic protozoan drug development to study its pharmacokinetics, metabolism, safety, efficacy and methods of delivery as an antimalarial drug.

Biochem/physiol Actions

Chlorguanide (proguanil) is combined with atovaquone for malaria prophylaxis. The two compounds act synergistically to inhibit the plasmodial dihydrofolate reductase (DHFR) and interrupt the electron transport chain. Mutations in DHFR account for the development of resistant strains.
Proguanil hydrochloride is antimalarial. Dihydrofolate reductase inhibitor

Features and Benefits

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.


Still not finding the right product?

Explore all of our products under 氯胍 盐酸盐


pictograms

Skull and crossbones

signalword

Danger

hcodes

Hazard Classifications

Acute Tox. 3 Oral

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库


商品

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.


Carine Van Malderen et al.
Malaria journal, 11, 139-139 (2012-05-02)
Malaria is a leading cause of mortality, particularly in sub-Saharan African children. Prompt and efficacious treatment is important as patients may progress within a few hours to severe and possibly fatal disease. Chlorproguanil-dapsone-artesunate (CDA) was a promising artemisinin-based combination therapy
Allan Pamba et al.
Blood, 120(20), 4123-4133 (2012-09-21)
Drug-induced acute hemolytic anemia led to the discovery of G6PD deficiency. However, most clinical data are from isolated case reports. In 2 clinical trials of antimalarial preparations containing dapsone (4,4'-diaminodiphenylsulfone; 2.5 mg/kg once daily for 3 days), 95 G6PD-deficient hemizygous
Miriam K Laufer et al.
PloS one, 7(8), e42284-e42284 (2012-08-23)
The predominance of chloroquine-susceptible falciparum malaria in Malawi more than a decade after chloroquine's withdrawal permits contemplation of re-introducing chloroquine for targeted uses. We aimed to compare the ability of different partner drugs to preserve chloroquine efficacy and prevent the



全球贸易项目编号

货号GTIN
G7048-50MG04061833642351
G7048-10MG04061833024195